300 related articles for article (PubMed ID: 17618322)
1. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease.
Perales MA; Ishill N; Lomazow WA; Weinstock DM; Papadopoulos EB; Dastigir H; Chiu M; Boulad F; Castro-Malaspina HR; Heller G; Jakubowski AA; O'Reilly RJ; Small TN; Young JW; Kernan NA
Bone Marrow Transplant; 2007 Sep; 40(5):481-6. PubMed ID: 17618322
[TBL] [Abstract][Full Text] [Related]
2. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
Wolff D; Wilhelm S; Hahn J; Gentilini C; Hilgendorf I; Steiner B; Kahl C; Junghanss C; Hartung G; Casper J; Uharek L; Holler E; Freund M
Bone Marrow Transplant; 2006 Sep; 38(6):445-51. PubMed ID: 16951692
[TBL] [Abstract][Full Text] [Related]
3. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
Wolff D; Roessler V; Steiner B; Wilhelm S; Weirich V; Brenmoehl J; Leithaeuser M; Hofmeister N; Junghanss C; Casper J; Hartung G; Holler E; Freund M
Bone Marrow Transplant; 2005 May; 35(10):1003-10. PubMed ID: 15806135
[TBL] [Abstract][Full Text] [Related]
4. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
Teachey DT; Bickert B; Bunin N
Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
[TBL] [Abstract][Full Text] [Related]
5. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.
Rao K; Rao A; Karlsson H; Jagani M; Veys P; Amrolia PJ
J Pediatr Hematol Oncol; 2009 Jun; 31(6):456-61. PubMed ID: 19648797
[TBL] [Abstract][Full Text] [Related]
6. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience.
Miano M; Cuzzubbo D; Terranova P; Giardino S; Lanino E; Morreale G; Castagnola E; Dini G; Faraci M
Bone Marrow Transplant; 2009 Mar; 43(5):423-7. PubMed ID: 18850021
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of children treated with daclizumab for steroid-refractory gastrointestinal GvHD in a prospective study.
Hamidieh AA; Hadjibabaie M; Ghehi MT; Jalili M; Hosseini A; Pasha F; Behfar M; Ghavamzadeh A
Pediatr Transplant; 2012 Sep; 16(6):664-9. PubMed ID: 22738324
[TBL] [Abstract][Full Text] [Related]
9. Infliximab treatment for steroid-refractory acute graft-versus-host disease.
Patriarca F; Sperotto A; Damiani D; Morreale G; Bonifazi F; Olivieri A; Ciceri F; Milone G; Cesaro S; Bandini G; Dini G; Corradini P; Fanin R
Haematologica; 2004 Nov; 89(11):1352-9. PubMed ID: 15531458
[TBL] [Abstract][Full Text] [Related]
10. Infliximab for GVHD therapy in children.
Sleight BS; Chan KW; Braun TM; Serrano A; Gilman AL
Bone Marrow Transplant; 2007 Sep; 40(5):473-80. PubMed ID: 17618323
[TBL] [Abstract][Full Text] [Related]
11. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
[TBL] [Abstract][Full Text] [Related]
12. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD.
Perfetti P; Carlier P; Strada P; Gualandi F; Occhini D; Van Lint MT; Ibatici A; Lamparelli T; Bruno B; Raiola AM; Dominietto A; Di Grazia C; Bregante S; Zia S; Ferrari GM; Stura P; Pogliani E; Bacigalupo A
Bone Marrow Transplant; 2008 Nov; 42(9):609-17. PubMed ID: 18660840
[TBL] [Abstract][Full Text] [Related]
13. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
14. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin.
Khoury H; Kashyap A; Adkins DR; Brown RA; Miller G; Vij R; Westervelt P; Trinkaus K; Goodnough LT; Hayashi RJ; Parker P; Forman SJ; DiPersio JF
Bone Marrow Transplant; 2001 May; 27(10):1059-64. PubMed ID: 11438821
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease.
Goldberg J; Jacobsohn DA; Zahurak ML; Vogelsang GB
Biol Blood Marrow Transplant; 2005 Feb; 11(2):101-7. PubMed ID: 15682070
[TBL] [Abstract][Full Text] [Related]
16. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease.
Mayer J; Krejcí M; Doubek M; Pospísil Z; Brychtová Y; Tomíska M; Rácil Z
Bone Marrow Transplant; 2005 Apr; 35(7):699-705. PubMed ID: 15696180
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Lee KH; Choi SJ; Lee JH; Lee JS; Kim WK; Lee KB; Sohn SK; Kim JG; Kim DH; Seol M; Lee YS; Lee JH
Haematologica; 2005 Jul; 90(7):939-48. PubMed ID: 15996932
[TBL] [Abstract][Full Text] [Related]
18. Infliximab for steroid-refractory acute GVHD: a case series.
Jacobsohn DA; Hallick J; Anders V; McMillan S; Morris L; Vogelsang GB
Am J Hematol; 2003 Oct; 74(2):119-24. PubMed ID: 14508798
[TBL] [Abstract][Full Text] [Related]
19. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
Murashige N; Kami M; Mori S; Katayama Y; Kobayashi K; Onishi Y; Hori A; Kishi Y; Hamaki T; Tajima K; Kanda Y; Tanosaki R; Takaue Y
Am J Hematol; 2008 Aug; 83(8):630-4. PubMed ID: 18454459
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease.
Bordigoni P; Dimicoli S; Clement L; Baumann C; Salmon A; Witz F; Feugier P
Br J Haematol; 2006 Nov; 135(3):382-5. PubMed ID: 16984386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
